TFAP2C Knockdown Sensitizes Bladder Cancer Cells to Cisplatin Treatment via Regulation of EGFR and NF-κB

TFAP2C Knockdown Sensitizes Bladder Cancer Cells to Cisplatin Treatment via Regulation of EGFR and NF-κB

Cisplatin is the first-line chemotherapy for advanced or metastatic bladder cancer. Nevertheless, approximately half of patients with BCa are insensitive to cisplatin therapy or develop cisplatin resistance during the treatment process. Therefore, it is especially crucial to investigate ways to enha...

Full description

Bibliographic Details
Main Authors: Ji Xing, Wu Chen, Kang Chen, Shaoming Zhu, Fangyou Lin, Yucheng Qi, Yunlong Zhang, Shangting Han, Ting Rao, Yuan Ruan, Sheng Zhao, Weimin Yu, Fan Cheng
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
bladder cancer
TFAP2C
cisplatin
EGFR
NF-κB
Online Access:https://www.mdpi.com/2072-6694/14/19/4809

Internet

https://www.mdpi.com/2072-6694/14/19/4809

Similar Items